T-DM1 for advanced HER2-positive breast cancer: the Royal Marsden Experience

  • Battisti NMLL & al.
  • Cancer Treat Res Commun
  • 27 Jun 2020

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Real-world data from the Royal Marsden Hospital show that the side effect profile of ado-trastuzumab emtansine (T-DM1) in the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is similar to that shown in clinical trials. However, there are a number of differences.

A study published in Cancer Treatment and Research Communications identified 128 patients with advanced HER2-positive breast cancer (median age, 55 years) on T-DM1 from 1 January 2014 to 12 March 2018.

Among participants, 89.8 per cent had Eastern Cooperative Oncology Group performance status 0-1 and 21.1 per cent had presented with de novo metastatic disease. More than half (57.8%) had estrogen receptor-positive disease, and 38.3 per cent had central nervous system involvement.

A total of 88.3 per cent of patients had received trastuzumab for advanced disease (with pertuzumab in 28.9%), and 11.7 per cent had only received trastuzumab in the adjuvant setting.

Grade ≥3 adverse events occurred in 35.9 per cent of patients - liver toxicity (19.5%), anaemia (6.2%) and thrombocytopenia (4.7%). Peripheral neuropathy of any grade was reported in 21.9 per cent of cases, bleeding in 9.4 per cent and ejection fraction decline in five patients.

Median progression-free survival was 8.7 months, and overall survival was 20.4 months. Prior pertuzumab did not influence survival outcomes.

The safety of T-DM1 in the Royal Marsden population is similar to that reported in clinical trials; however, this study found higher rates of peripheral neuropathy and deranged liver function.